U.S. new coronary pneumonia patients effective this drug 2 days after The Chinese clinical trial

The reporter learned from Gilead Science that its clinical trial of the new drug Remdesivir (Redsivir) to treat the new coronavirus (2019-nCoV) pneumonia will be launched on February 3 at the Sino-Japanese Friendship Hospital in Beijing. It is reported that Gilead will cooperate with China’s health department to carry out a randomized, controlled trial to determine whether the use of Remdesivir treatment 2019-nCoV infected people is safe and effective.

Remdesivir is a nucleotide analogue that inhibits RNA-dependent RNA synthesis assases (RdRp). The drug, originally developed for the Ebola virus, has just been shown to be effective against pneumonia, a new coronavirus infection, in a case in the United States.

On January 31st, local time, the leading medical journal, the New England Journal of Medicine, published details of the diagnosis and treatment of a man in his 30s who had contracted the new coronavirus pneumonia in the United States.

U.S. new coronary pneumonia patients effective this drug 2 days after The Chinese clinical trial

According to the New England Journal of Medicine, the man began using intravenous Redesivir on the night of the seventh day of admission (the 11th day of his illness) and did not observe adverse events associated with infusions. After continuous calcitonin levels and nasal PCR testing of Methicillin-resistant Staphylococcus aureus, vancomycin was discontinued on the 7th night and cephalosporine was discontinued the following day.

The following day, the patient’s clinical condition improved. Stopping the oxygen supplement, his oxygen saturation increased to 94% to 96% while breathing the surrounding air. The previous two-sided lower leaf tone no longer exists. His appetite improved and he had no symptoms except intermittent dry cough and snot. As of January 30, 2020, the patient remains hospitalized. He has a fever, all symptoms except a cough have eased, and the degree of cough ingenasis is easing.

The patient’s previous chest X-rays showed that both lungs had a substrate-like cloud, consistent with atypical pneumonia.

On the same day, Merdad Parsey, global chief medical officer of Gilead Sciences, issued a statement on behalf of the company, saying that Gilead is working closely with health agencies around the world to provide the research drug Remdesivir for experimental treatment to support the response to the outbreak of the new coronary virus infection.

Gilead said that while there is no antiviral data showing Remdesivir’s activity for 2019-nCoV, its valid data for other coronaviruses gives us hope. In in vitro and animal models, Remdesivir confirmed that viral pathogens of atypical pneumonia (SARS) and Middle East Respiratory Syndrome (MERS) are active, they are also coronaviruses, and are structurally similar to 2019-nCoV. Clinical data on Remdesivir (Redsivir) emergency use to treat ebola virus infection sisivir are also limited.

In addition, Gilead is working with organizations such as the China Center for Disease Control and Prevention, The National Drug Administration (NMPA) and researchers and clinicians to fight the new coronavirus. Gilead will work with China’s health department to conduct a randomized, controlled trial to determine whether using Remdesivir to treat people infected in 2019-nCoV is safe and effective. At the same time, the company is also promoting appropriate laboratory testing of Remdesivir using 2019-nCoV virus samples.

Gilead Sciences is a research-based biopharmaceutical company in the United States that develops and sells drugs. Gilead’s main focus areas include human immunodeficiency virus (HIV)/AIDS, liver diseases such as hepatitis B and C and cardiovascular/metabolic and respiratory conditions.

On January 24th, a report by the Shanghai Public Health Clinical Center, “Public Health And Cop” Weapons! In the face of new types of pneumonia, we are not helpless – 2019 New Coronary Virus Antiviral Treatment Options also mentions that, from current research data, Remdesivir may be the most promising anti-viral drug.

The author of this article is Lu Hongzhou, a well-known infectious disease expert and party secretary of the Shanghai Public Health Clinical Center affiliated with Fudan University.

‘Remdesivir (RDV, GS-5734) is a new nucleoside analogue antiviral, Lu Hongzhou wrote in the above article. Nucleoside analogues can be used to resist viral therapy by inhibiting the synthesis of viral nucleic acids. RDV is currently being studied primarily as an experimental drug for the Ebola virus, which has strong anti-filament virus effect in vitro, and has now completed Phase III clinical trials.

Subsequent studies have found that RDV is not only effective for silk viruses such as the Ebola virus, but also inhibits respiratory syncytial viruses, coronaviruses, Nipah viruses, and Hendra viruses.

Lu Hongzhou pointed out that animal experiments have shown that preventive and early use of RDV can significantly reduce the level of lung tissue viral load in MICE infected with SARS-CoV, MERS-CoV, while improving lung function and alleviating symptoms. “From current research data, RDV is probably the most promising anti-viral drug. However, no studies have been made on the safety and efficacy of RDV in humans. “

In a note published on the website of the New England Journal of Medicine and the Lancet, the China New Crown Pneumonia Research Group also noted that Remdesivir, the AIDS compound, The Lopinavir-Litonavir tablet (commodity name: Creech) and interferon, have achieved good results in animal models of the MERMER virus. The effects of treating new coronavirus infection pneumonia are currently being evaluated.

The New England Journal of Medicine also notes in the article that, despite the decision to give the patient an intravenous retdesivir treatment, according to the patient’s deteriorating clinical condition, Randomized controlled trials are required to determine the safety and efficacy of remdesivir and any other research drug treatments for 2019-nCoV infection.